clinvest@mail.ruГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», МоскваRussian FederationРоссийский государственный медицинский университет, г. МоскваRussian FederationООО "Центр фармакоэкономических исследований", г. МоскваRussian Federation200223062018016270Copyright © Белоусов Ю.Б., Грацианский Н.А., Бекетов А.С., 20182018Белоусов Ю.Б., Грацианский Н.А., Бекетов А.С.Белоусов Ю.Б., Грацианский Н.А., Бекетов А.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/240фармакоэкономикааторвастатинишемическая болезнь сердцагиполипидемические средстваReferencesЗдоровье населения России и деятельность учреждений здравоохранения в 1998 (1999) г. (статистические материалы). М., 1999 (2000).Здоровье населения России и деятельность учреждений здравоохранения в 1998 (1999) г. (статистические материалы). М., 1999 (2000).Neaton J., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch. Intern. Med., 1992, 152, 56-64.Neaton J., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch. Intern. Med., 1992, 152, 56-64.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.Доборджгинидзе Л.М., Грацианский Н.А. Статины: достижения и новые перспективы // РМЖ, 2001, т. 9, №18, http://http://www.rmj.ru/main.htm/rmj/t9/n18/758.htmДоборджгинидзе Л.М., Грацианский Н.А. Статины: достижения и новые перспективы // РМЖ, 2001, т. 9, №18, http://http://www.rmj.ru/main.htm/rmj/t9/n18/758.htmПрофиль, №41, от 5.11.2001, с.39 (по материалам Dean Foust et. All. «Business Week»).Профиль, №41, от 5.11.2001, с.39 (по материалам Dean Foust et. All. «Business Week»).Майрон Д. Дж. и др. Современные перспективы применения статинов // Международный медицинский журнал», №6,2000, http://medi.ru/doc/77.htmМайрон Д. Дж. и др. Современные перспективы применения статинов // Международный медицинский журнал», №6,2000, http://medi.ru/doc/77.htmKoren M.J. et аl. The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. Pharmacoeconomics 1998, Jul, 14 (1): 59-70.Koren M.J. et аl. The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. Pharmacoeconomics 1998, Jul, 14 (1): 59-70.Doggrell S.A. Statins in the 21st Century: End of the Simple Story. Expert Opin. Investig. Drugs (2001), 10 (9), 1755-1764.Doggrell S.A. Statins in the 21st Century: End of the Simple Story. Expert Opin. Investig. Drugs (2001), 10 (9), 1755-1764.Schwartz G. et аl. Effects of Atorvastatin on Early Recurrent Ischemic Eventsin Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial., JAMA, April 4, 2001—Vol. 285, No. 13, 1713-1718.Schwartz G. et аl. Effects of Atorvastatin on Early Recurrent Ischemic Eventsin Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial., JAMA, April 4, 2001—Vol. 285, No. 13, 1713-1718.Stenestrand U. et аl. Early Statin Treatment Following Acute Myocardial Infarction and 1'Year Survival. JAMA, January 24/31, 2001—Vol 285, No. 4 430-436.Stenestrand U. et аl. Early Statin Treatment Following Acute Myocardial Infarction and 1'Year Survival. JAMA, January 24/31, 2001—Vol 285, No. 4 430-436.Falk E. et аl. Coronary Plaque Disruption. Circulation 1995; 92:657-671.Falk E. et аl. Coronary Plaque Disruption. Circulation 1995; 92:657-671.Фуркало С.Н. Реваскуляризация миокарда – коронарное шунирование или ангиопластика? // Український кардіологічний журнал, 1999, №6, с. 5-11.Фуркало С.Н. Реваскуляризация миокарда – коронарное шунирование или ангиопластика? // Український кардіологічний журнал, 1999, №6, с. 5-11.Editorial, «BARI, CABRI, EAST, Gabi and RITA: coronary angioplasty on trial.», Lancet 1990; 335:1315-16.Editorial, «BARI, CABRI, EAST, Gabi and RITA: coronary angioplasty on trial.», Lancet 1990; 335:1315-16.Кохан Е.П. и др. Нестабильная стенокардия. М., 2000.Кохан Е.П. и др. Нестабильная стенокардия. М., 2000.Campeau L. et аl. The Post Coronary Artery Bypass Graft Trial Investigators. The Effect of Aggressive Lowering of Low'Density Lipoprotein Cholesterol Levels and Low'Dose Anticoagulation on Obstructive Changes in Saphenous'Vein Coronary–Artery Bypass Graft.», N. Engl. J. Med., 1997, 336: 153-162.Campeau L. et аl. The Post Coronary Artery Bypass Graft Trial Investigators. The Effect of Aggressive Lowering of Low'Density Lipoprotein Cholesterol Levels and Low'Dose Anticoagulation on Obstructive Changes in Saphenous'Vein Coronary–Artery Bypass Graft.», N. Engl. J. Med., 1997, 336: 153-162.Бокерия Л.А., Гудкова Р.Г. Здоровье населения Российской Федерации и хирургическое лечение болезней сердца и сосудов в 1998 г. 'М.: Изд-во НЦССХ им А.Н. Бакулева РАМН, 1999.Бокерия Л.А., Гудкова Р.Г. Здоровье населения Российской Федерации и хирургическое лечение болезней сердца и сосудов в 1998 г. 'М.: Изд-во НЦССХ им А.Н. Бакулева РАМН, 1999.Smilde T.J. et аl. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial., THE LANCET Vol 357, February 24, 2001, 577-581.Smilde T.J. et аl. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial., THE LANCET Vol 357, February 24, 2001, 577-581.Waters D. Comparison of Aggressive Lipid Lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and Conventional Care for the Reduction of Ischemic Events in Patients with Stable Coronary Artery Disease., Cardiovasc. Rev. Rep. 21 (1):26-31, 2000.Waters D. Comparison of Aggressive Lipid Lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and Conventional Care for the Reduction of Ischemic Events in Patients with Stable Coronary Artery Disease., Cardiovasc. Rev. Rep. 21 (1):26-31, 2000.Грацианский Н.А. Нестабильная стенокардия – острый коронарный синдром. III. Предупреждение обострений ишемической болезни сердца. Статины и антибиотики // Кардиология, №11, 1997, с. 4-17.Грацианский Н.А. Нестабильная стенокардия – острый коронарный синдром. III. Предупреждение обострений ишемической болезни сердца. Статины и антибиотики // Кардиология, №11, 1997, с. 4-17.Herrera M. et аl. Reduction of Rates of Restenosis after Coronary Angioplasty with Simvastatin and Probucol. (Abstract), Rev. Esp. Cardiol.,1999, Oct; 52 (10): 778-784.Herrera M. et аl. Reduction of Rates of Restenosis after Coronary Angioplasty with Simvastatin and Probucol. (Abstract), Rev. Esp. Cardiol.,1999, Oct; 52 (10): 778-784.Lerner D.J.; Kannel W.B. Patterns of coronary heart desease morbidity and mortality in the sexes: A twenty-six year follow-up of the Framingham population. Am Heart J 1986; 111:383-90.Lerner D.J.; Kannel W.B. Patterns of coronary heart desease morbidity and mortality in the sexes: A twenty-six year follow-up of the Framingham population. Am Heart J 1986; 111:383-90.Martin M. J. et al. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361662 men. Lancet 1986; 2:933-36.Martin M. J. et al. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361662 men. Lancet 1986; 2:933-36.Hebert P.R., Gaziano J.M. et al. Cholesterol lowering with statin drug, risk of stroke and total mortality. JAMA 1997; 278:313-321.Hebert P.R., Gaziano J.M. et al. Cholesterol lowering with statin drug, risk of stroke and total mortality. JAMA 1997; 278:313-321.Jones P. et al. Comparative Dose Efficacy Study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). Am J Card. 1998; V81; Issue 5:582-587Jones P. et al. Comparative Dose Efficacy Study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). Am J Card. 1998; V81; Issue 5:582-587Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97http://www.government.gov.ruhttp://www.government.gov.ruStaffa J.A., Chang J., Green L., Cerivastatin and reports of fatal rhabdomyolysis. New Eng J Med, Vol. 346: 539-540, No. 7 · Feb. 14, 2002Staffa J.A., Chang J., Green L., Cerivastatin and reports of fatal rhabdomyolysis. New Eng J Med, Vol. 346: 539-540, No. 7 · Feb. 14, 2002http://www.d-vizion.ruhttp://www.d-vizion.ruPrevention of Coronary Heart Disease in Clinical Practice. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:1434-1503.Prevention of Coronary Heart Disease in Clinical Practice. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:1434-1503.
The authors declare that there are no conflicts of interest present.